1300 completed, 250 recruiting, 243 terminated, 203 unknown. 2324 Phase 2, 435 Phase 1, 221 Phase 3.
Follow Neurodegenerative Diseases: new trials by email Literature Review of Neurodegenerative Diseases trials Research Report on Neurodegenerative Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin And Metabolic Energetics in Parkinson's Disease Terazosin 5 MG, Placebo - Parkinson's Disease (PD) | Phase 2 | Suspended | Ergun Y. Uc | 120 | 2028-07-01 | 2026-10-09 |
| Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease | Phase 2 | Withdrawn | Forest Hills Lab | 2027-11-01 | 2026-08-19 | |
| Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies | Phase 1 / Phase 2 | Not yet recruiting | Qiang Zhang | 40 | 2027-10-01 | 2026-03-12 |
| AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease AV-1959R, Placebo - Preclinical Alzheimer's Disease, Alzheimer Disease | Phase 2 | Not yet recruiting | Institute for Molecular Medicine | 160 | 2027-10-01 | 2026-10-21 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease MT101-5 - Parkinson's Disease | Phase 2 | Not yet recruiting | Mthera Pharma Co., Ltd. | 120 | 2027-09-01 | 2026-10-16 |
| Terazosin And Metabolic Engagement in Alzheimer's Disease Terazosin (Hytrin), Placebo - Alzheimer s Disease | Phase 2 | Not yet recruiting | Qiang Zhang | 100 | 2027-08-01 | 2026-09-01 |
| Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A scAAV1.tMCK.NTF3 - Charcot-Marie-Tooth Neuropathy Type 1A | Phase 1 / Phase 2 | Withdrawn | Nationwide Children's Hospital | 2027-04-01 | 2026-07-29 | |
| Sustained Release Oral Formulation For Treatment Of Parkinsons Disease Formulation A, Formulation B, Formulation C - Healthy Volunteers | Phase 1 / Phase 2 | Not yet recruiting | University of Minnesota | 32 | 2027-04-01 | 2026-10-01 |
| A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD) AB-1005 - Parkinson Disease | Phase 2 | Not yet recruiting | Bayer | 8 | 2027-01-25 | 2026-07-29 |
| Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma mirdametinib with radiation, mirdametinib - Neurofibromatosis 1 (NF1) | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 55 | 2027-01-01 | 2026-10-05 |
| Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor) | Phase 2 | Not yet recruiting | Girish Dhall, MD | 25 | 2027-01-01 | 2026-10-28 |
| Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease Talineuren, Placebo - Parkinson Disease | Phase 2 | Not yet recruiting | InnoMedica Schweiz AG | 40 | 2027-01-01 | 2026-10-30 |
| Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia Intravenous infusion, Intrathecal injection, umbilical cord mesenchymal stem cell - Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2 | Phase 2 | Not yet recruiting | Sclnow Biotechnology Co., Ltd. | 45 | 2026-12-31 | 2026-04-23 |
| Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 40 | 2026-12-31 | 2026-10-28 |
| Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease Sitagliptin, Sitagliptin placebo - Parkinson Disease | Phase 2 | Not yet recruiting | Yonsei University | 160 | 2026-12-15 | 2026-09-10 |
| A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease 60 milligrams of ENERGI-F705 Tablets, Placebo tablets, 120 milligrams of ENERGI-F705 Tablets - Parkinson's Disease (PD) | Phase 2 | Not yet recruiting | Energenesis Biomedical Co., Ltd. | 105 | 2026-12-01 | 2026-07-02 |
| Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) Q-Cells - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | Q Therapeutics, Inc. | 30 | 2026-12-01 | 2026-07-08 |
| Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS nL-TARDB-002 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Enrolling by invitation | n-Lorem Foundation | 1 | 2026-12-01 | 2026-07-14 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism Intrathecal (IT), Intravenous - Parkinsonism or Parkinson's Disease Nos, Parkinsonism in Diseases Classified Elsewhere | Phase 2 | Not yet recruiting | Biocells Medical | 120 | 2026-11-23 | 2026-03-13 |
Showing 20 of 2324. Sign in to see all of them.
Alzheimer Disease (713) · Parkinson Disease (601) · Amyotrophic Lateral Sclerosis (274) · Dementia (168) · Cognitive Dysfunction (160) · Huntington Disease (76) · Hereditary Sensory and Autonomic Neuropathies (75) · Myasthenia Gravis (57) · Neurofibromatosis 1 (55) · Nervous System Diseases (50) · Central Nervous System Diseases (49) · Dyskinesias (45) · Tourette Syndrome (45) · Brain Diseases (43)
Nervous System Diseases (2274) · Central Nervous System Diseases (1949) · Brain Diseases (1611) · Mental Disorders (944) · Neurocognitive Disorders (855) · Basal Ganglia Diseases (810) · Movement Disorders (779) · Tauopathies (724) · Dementia (695) · Synucleinopathies (654) · Parkinsonian Disorders (614) · Neuromuscular Diseases (584) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (546) · Genetic Diseases, Inborn (529)
Donepezil (40) · Levodopa (31) · carbidopa, levodopa drug combination (23) · Sodium Chloride (22) · Sirolimus (20) · Riluzole (18) · Saline Solution (18) · florbetapir (18) · AZD 6244 (17) · Everolimus (17) · Sugars (17) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (13) · Carbidopa (13) · Memantine (13) · Levetiracetam (12)
Novartis Pharmaceuticals (34) · Pfizer (34) · National Institute of Neurological Disorders and Stroke (NINDS) (32) · Chang Gung Memorial Hospital (22) · Hoffmann-La Roche (22) · Massachusetts General Hospital (19) · Eli Lilly and Company (17) · Avid Radiopharmaceuticals (16) · Biogen (16) · Assistance Publique - Hôpitaux de Paris (14) · GlaxoSmithKline (14) · Merck Sharp & Dohme LLC (14) · NYU Langone Health (14) · Columbia University (13) · Eisai Inc. (13)
United States (1337) · Canada (284) · France (282) · Germany (261) · United Kingdom (260) · Spain (235) · Italy (225) · Australia (160) · Netherlands (145) · Poland (128) · China (122) · Japan (109) · Belgium (104) · South Korea (79) · Sweden (71)
Merit Cudkowicz, MD (10) · Suzanne Craft, PhD (8) · Danna Jennings, MD (6) · Ilise Lombardo, MD (6)
PMID 36463457, PMID 36602886, PMID 38588457, PMID 33974419, PMID 38489195, PMID 40680102, PMID 41224659, PMID 25918556, PMID 31356217, PMID 39800465, PMID 40603145, PMID 28029918, PMID 29480210, PMID 32187457, PMID 32250312, PMID 33189083, PMID 34532852, PMID 36008843, PMID 37148485, PMID 38706271, PMID 40368603, PMID 15683544, PMID 17105749, PMID 17941858, PMID 21484867, PMID 21996156, PMID 22353803, PMID 24001701, PMID 24144615, PMID 24327518, PMID 24412048, PMID 24711047, PMID 25669746, PMID 25731629, PMID 25988365, PMID 26751635, PMID 26763495, PMID 26851632, PMID 26967206, PMID 26967214, PMID 27214258, PMID 27424289, PMID 27494299, PMID 27756421, PMID 27871675, PMID 27939059, PMID 28202705, PMID 28230061, PMID 28409229, PMID 28672195
2023 (41), 2016 (24), 2025 (24), 2017 (18), 2018 (18), 2009 (17), 2014 (16), 2015 (13), 2019 (12), 2008 (7), U01AG059798 (5), R01AG046179 (4), U01AG042791 (4), 2005 (3), K23AG052633 (3)